TNFRSF4
Tumor necrosis factor receptor superfamily member 4
As of the edition of 20 October 2026, TNFRSF4 (tumor necrosis factor receptor superfamily member 4, UniProt P43489) has 11 drugs tested at it and 13 companies on the list, 8 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43489
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 8
- Disease areas
- Cancer; Skin and connective tissue; Immune system; Inherited and neonatal; Urinary and reproductive; Lungs and airways; Pregnancy and women's health; Digestive system
- Registered trials of its drugs
- 52
Drugs at this target
| Status | Count |
|---|---|
| Active | 3 |
| Went quiet | 3 |
| Stopped | 5 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Rocatinlimab | Stopped | Phase 3 | none listed |
| Ivuxolimab | Active | Phase 3 | none listed |
| GSK-3174998 | Stopped | Phase 2 | none listed |
| MEDI-6469 | Stopped | Phase 2 | none listed |
| ES102 | Active | Phase 2 | none listed |
| INBRX-106 | Active | Phase 3 | none listed |
| Vonlerolizumab | Went quiet | Phase 2 | none listed |
| BAT6026 | Stopped | Phase 1 | none listed |
| INCAGN01949 | Went quiet | Phase 2 | none listed |
| Telazorlimab | Went quiet | Phase 2 | none listed |
| HFB301001 | Stopped | Phase 1 | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Engaged | 5 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| Amgen | Route A |
| GSK | Route A |
| AstraZeneca | Route A |
The other 10 companies at TNFRSF4
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at TNFRSF4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.